IMRX
USDImmuneering Corporation Class A Common Stock
वास्तविक समय मूल्य
मूल्य चार्ट
मुख्य मीट्रिक्स
बाजार मीट्रिक्स
खुलना
$1.320
उच्च
$1.320
कम
$1.210
मात्रा
0.02M
कंपनी के मौलिक सिद्धांत
बाजार पूंजीकरण
44.6M
उद्योग
जैव प्रौद्योगिकी
देश
United States
ट्रेडिंग आँकड़े
औसत मात्रा
0.20M
एक्सचेंज
NGM
मुद्रा
USD
52-सप्ताह रेंज
संबंधित समाचार
Chardan Capital Maintains Buy on Immuneering, Maintains $13 Price Target
Chardan Capital analyst Geulah Livshits maintains Immuneering with a Buy and maintains $13 price target.
Immuneering Corporation Announces Grant of Inducement Award
CAMBRIDGE, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for
Needham Reiterates Buy on Immuneering, Maintains $12 Price Target
Needham analyst Ami Fadia reiterates Immuneering with a Buy and maintains $12 price target.
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced a clinical
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of
संबंधित स्टॉक
NRC
National Research Corporation (Delaware)
SXTC
China SXT Pharmaceuticals Inc. Ordinary Shares
FHTX
Foghorn Therapeutics Inc.
GLYC
GlycoMimetics Inc.
LSBPW
LakeShore Biopharma Co. Ltd Warrants
अपडेट रहें
मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।